The MHRA's London Region I AI Regulatory Sandbox is not a pharmaceutical wholesale programme, but it matters to the broader medicines ecosystem. It shows the direction of travel: healthcare innovation is moving towards real-world evidence, controlled deployment, clearer governance and regulator-supervised learning.
The MHRA announced the sandbox in June 2026 and updated the page on 30 July 2026 to include the call for expressions of interest. AI medical device manufacturers and London-based NHS providers are invited to apply to support evaluation of AI-enabled medical devices in real-world NHS settings.
What the sandbox is trying to do
The programme is designed as a secure environment for safely testing AI-enabled devices. The MHRA says up to 10 AI medical device manufacturers will be selected for the initial phase, working with NHS providers under MHRA oversight.
The aim is to generate robust real-world evidence on safety and effectiveness while supporting a clearer route to wider adoption. That language is important. It frames innovation around evidence and governance, rather than speed alone.
Why pharma supply teams should pay attention
As AI becomes more common in healthcare operations, supply-chain partners will see more systems that influence forecasting, clinical workflows, procurement, product information, documentation and risk management. Even when AI is not making a clinical decision, it can still affect how work is prioritised and how information moves.
For pharmaceutical wholesalers, the useful question is not whether AI is fashionable. It is whether a system improves traceability, exception handling, stock visibility, compliance records or customer communication without weakening governance.
Practical principles for responsible adoption
Pharmaceutical organisations considering AI-enabled operational tools should start with practical controls:
- define whether the tool supports operations, clinical decisions, diagnosis or treatment;
- keep human review where the output affects regulated or patient-facing decisions;
- record how data is sourced, stored and checked;
- test whether the system improves real workflows, not just dashboards;
- review any change in product functionality that could affect regulatory status.
That approach also fits the existing Logan article on AI in pharmaceutical wholesale. The 2026 MHRA sandbox adds a current UK regulatory example to that broader supply-chain discussion.
Sources
Primary source: MHRA: Pioneering AI health innovations regulatory sandbox launched, accessed 30 July 2026.